Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update
Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update
Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update
Alpha Cognition Inc. (ACOG) Q1 2025 Earnings Call Transcript
Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer's disease
CSE Bulletin: Delist - Alpha Cognition Inc. (ACOG)
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
Alpha Cognition Announces Appointment of VP Finance and Accounting
Alpha Cognition Announces Change of Officer
Spartan Capital Securities Serves as Selling Group Member in Alpha Cognition Inc.'s $4.454 Million Convertible Note and Warrants Bridge Financing
Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge Financing
Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
Alpha Cognition Announces First Quarter of 2024 Results and Provides Corporate Update
Alpha Cognition Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
Alpha Cognition to Present at the Emerging Growth Conference on April 3, 2024 at 12:00pm EDT.
Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer's Disease
Alpha Cognition Provides Business Update
Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment
Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering
Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer's Disease
Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering
Alpha Cognition Announces Third Quarter and Nine Months Ended September 30, 2023, Results and Provides Corporate Update
Alpha Cognition Announces Third Closing of Private Placement and Continuation of the Offering
Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering
Alpha Cognition Announces Submission of New Drug Application to the FDA for ALPHA-1062 for Mild-to-Moderate Alzheimer's Disease
Alpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the Offering
Alpha Cognition Announces Second Quarter and Six Months Ended 2023 Results and Provides Corporate Update
Alpha Cognition Receives Notice of Allowance for U.S. Patent Application covering use of ALPHA-1062 for Mild to Moderate Alzheimer's Disease
Alpha Cognition to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023 & 1x1 Meetings on Thursday, April 27, 2023
Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease